昆明圣火药业（集团）有限公司是一家在美国全美证券交易所主版上市的国家高新技术产业化示范工程企业。企业初建于1996年5月，目前注册资本为￥7926万元人民币。公司致力于云南特产地道名贵药材三七的深加工开发和综合利用，十年磨一剑，已形成集科研、生产、销售为一体，资产总额达2.6亿元的企业集团。公司先后获得国家、省、市多项殊荣，属国家科技部、国家商务部、国家中医药管理局及省市政府重点扶持的民营高新科技企业.

Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. (“the Company,” “China Shenghuo”) is a leading specialtypharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd (“Kunming Shenghuo”), it owns thirty-one SFDA (State Food and Drug Association)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine into 1,650 hospitals and 1,500 drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Thailand and Kyrgyzstan